Shah G A, Dhall T Z, Ferguson I, Davis M R, Graham D T, Pomeroy A R, Dhall D P
J Clin Pathol. 1980 Jun;33(6):562-5. doi: 10.1136/jcp.33.6.562.
The potencies of six commercially manufactured heparins have been measured by the British Pharmacopoeial (BP) assay and activated partial thromboplastin time (APTT), protamine sulphate, and anti-Xa assays. The APTT/BP potency ratios were found to vary with the preparation but this was not dependent on the tissue source of heparin. For mucosal heparins, the anti-Xa/BP potency ratios were close to unity, but for heparin of lung origin the anti-Xa potency was approximately one-quarter of the BP potency. Four heparin fractions prepared by column gel chromatography of a commercial heparin were similarly examined by all four assays, and there was a wide divergence between the BP potency estimates and those obtained with the other methods. The degree of divergence was found to depend on the molecular size of the fraction.
已通过英国药典（BP）测定法、活化部分凝血活酶时间（APTT）、硫酸鱼精蛋白和抗Xa测定法对六种商业生产的肝素的效价进行了测量。发现APTT/BP效价比随制剂而异，但这并不取决于肝素的组织来源。对于粘膜肝素，抗Xa/BP效价比接近1，但对于肺源性肝素，抗Xa效价约为BP效价的四分之一。通过柱凝胶色谱法从一种商业肝素制备的四个肝素级分同样通过所有四种测定法进行了检测，BP效价估计值与其他方法获得的效价估计值之间存在很大差异。发现差异程度取决于级分的分子大小。
